Key stats
About SPDR S&P Pharmaceuticals ETF
Expense ratio
0.35%
Home page
Inception date
Jun 19, 2006
XPH offers equal-weighted exposure to a narrow selection of US pharmaceutical companies, stretching across all market caps. XPH's weighting scheme causes it to be far less concentrated than the industry, which is dominated by a handful of mega-cap names like J&J, Pfizer and Merck. The fund also introduces a heavy tilt to mid- and small-caps, which makes for a rather volatile fund relative to the industry. Overall, XPH is a solid way to capture a less concentrated version of the pharma market. The index is rebalanced quarterly.
Classification
What's in the fund
Exposure type
Health Technology
Stock breakdown by region
Displays a symbol's price movements over previous years to identify recurring trends.